ipharmaservicesOct 13US FDA Approved Pfizer's Hympavzi for hemophilia A or B, who do not have inhibitors | FDA Approved | iPharmaCenter
ipharmaservicesOct 13Roche aims to strengthen its breast cancer portfolio with the approval of Itovebi | FDA Approval | iPharmaCenter
ipharmaservicesOct 9US FDA Approved Opdivo as perioperative treatment in patients with resectable non-small cell lung cancer | iPharmaCenter
ipharmaservicesAug 24FDA Grants Accelerated Approval to Gilead’s Livdelzi for PBC, Marking Breakthrough in Liver Disease Treatment | iPharmaCenter
ipharmaservicesAug 8Novartis Gains FDA Accelerated Approval for Fabhalta (iptacopan), a Complement Inhibitor for Reducing Proteinuria in Primary IgA Nephropathy (IgAN)
ipharmaservicesAug 5US FDA Approves Expanded Use of Jemperli Plus Chemotherapy for Endometrial Cancer
ipharmaservicesJun 20Imfinzi approved for mismatch repair deficient endometrial cancer, fifth indication for AZ's blockbuster | iPharmaCenter
ipharmaservicesJun 19FDA Approved Skyrizi for Ulcerative Colitis, Enhancing AbbVie's Inflammatory Bowel Disease Portfolio
ipharmaservicesJun 18FDA Approved Merck’s Keytruda Plus Chemotherapy for Advanced or Recurrent Endometrial Carcinoma
ipharmaservicesMay 31FDA Approved Bristol Myers Squibb’s Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma
ipharmaservicesMay 16FDA approved BMS' Breyanzi for relapsed or refractory follicular lymphoma | iPharmaCenter
ipharmaservicesApr 30FDA Grants Complete Approval for Tivdak in Treating Recurrent or Metastatic Cervical Cancer
ipharmaservicesMar 20FDA approved Orchard Therapeutics' Lenmeldy for juvenile metachromatic leukodystrophy | FDA Approvals | News | iPharmaCenter
ipharmaservicesMar 16FDA Gives Green Light to First Medication for Individuals with Liver Scarring Stemming from Fatty Liver Condition | iPharmaCenter
ipharmaservicesNov 30, 2023FDA Greenlights First Treatment for Uncommon Non-Cancerous Growth | FDA Approvals | iPharmaCenter
